Design and characterization of lipid nanocarriers for oral delivery of immunotherapeutic peptides
Source abstract
Abstract
Abstract The use of therapeutic proteins and peptides is of great interest for the treatment of many diseases, and advances in nanotechnology offer a path toward their stable delivery via preferred routes of administration. In this study, we sought to design and formulate a nanostructured lipid carrier (NLC) containing a nominal antigen (insulin peptide) for oral delivery. We utilized the design of experiments (DOE) statistical method to determine the dependencies of formulation variables on physicochemical particle characteristics including particle size, polydispersity (PDI), melting point, and latent heat of melting. The particles were determined to be non‐toxic in vitro , readily taken up by primary immune cells, and found to accumulate in regional lymph nodes following oral administration. We believe that this platform technology could be broadly useful for the treatment of autoimmune diseases by supporting the development of oral delivery‐based antigen specific immunotherapies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Johns Hopkins Applied Physics Laboratory Laurel Maryland USA
Department of Plastic & Reconstructive Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
References (47)
Show source-provided references
1. 10.1002/eji.20174705910.1002/eji.201747059 ↗
2. 10.1016/j.ejpb.2017.03.01510.1016/j.ejpb.2017.03.015 ↗
3. 10.1007/s12272-020-01219-010.1007/s12272-020-01219-0 ↗
4. 10.1002/adhm.20200016410.1002/adhm.202000164 ↗
5. 10.1021/acs.jmedchem.7b0031810.1021/acs.jmedchem.7b00318 ↗
6. 10.1007/s40199-019-00316-w10.1007/s40199-019-00316-w ↗
7. 10.3109/10717544.2013.81961110.3109/10717544.2013.819611 ↗
8. 10.1016/j.ijpharm.2018.02.03810.1016/j.ijpharm.2018.02.038 ↗
9. 10.1016/j.addr.2020.06.00310.1016/j.addr.2020.06.003 ↗
10. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
11. 10.1016/j.addr.2003.12.00210.1016/j.addr.2003.12.002 ↗
12. Advanced drug delivery to the lymphatic system: lipid‐based nanoformulations
13. 10.1016/j.ijpharm.2013.03.03410.1016/j.ijpharm.2013.03.034 ↗
14. 10.1016/j.ijpharm.2013.03.03610.1016/j.ijpharm.2013.03.036 ↗
15. 10.3892/ijmm.2012.108610.3892/ijmm.2012.1086 ↗
16. 10.1038/nrd460810.1038/nrd4608 ↗
17. 10.3390/molecules2505116110.3390/molecules25051161 ↗
18. 10.1016/j.jconrel.2016.07.05010.1016/j.jconrel.2016.07.050 ↗
19. 10.1016/j.nano.2018.10.00110.1016/j.nano.2018.10.001 ↗
20. 10.1038/s41587-019-0015-410.1038/s41587-019-0015-4 ↗
21. 10.1016/j.coi.2021.03.01910.1016/j.coi.2021.03.019 ↗
22. 10.1016/j.addr.2018.12.00310.1016/j.addr.2018.12.003 ↗
23. 10.1056/NEJMra191110910.1056/NEJMra1911109 ↗
24. 10.1016/S0939-6411(03)00067-510.1016/S0939-6411(03)00067-5 ↗
25. 10.1016/j.ijpharm.2006.08.00710.1016/j.ijpharm.2006.08.007 ↗
26. 10.1006/jaut.1994.106610.1006/jaut.1994.1066 ↗
27. 10.1084/jem.2011057410.1084/jem.20110574 ↗
28. 10.3791/5310210.3791/53102 ↗
29. 10.1021/acs.nanolett.1c0250310.1021/acs.nanolett.1c02503 ↗
30. 10.1021/acs.nanolett.5b0352810.1021/acs.nanolett.5b03528 ↗
31. Hydrophobic ion pairing of an insulin‐sodium deoxycholate complex for oral delivery of insulin
32. 10.1016/j.cis.2003.10.02310.1016/j.cis.2003.10.023 ↗
33. 10.1021/la001362n10.1021/la001362n ↗
34. 10.4049/jimmunol.090093610.4049/jimmunol.0900936 ↗
35. 10.3389/fimmu.2018.0156510.3389/fimmu.2018.01565 ↗
36. 10.1080/17425247.2017.126632910.1080/17425247.2017.1266329 ↗
37. AttamaA MomohMA BuildersPF.Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development;2012.
38. 10.2337/db11-067110.2337/db11-0671 ↗
39. 10.1371/journal.pone.011224210.1371/journal.pone.0112242 ↗
40. 10.3390/pharmaceutics1112067910.3390/pharmaceutics11120679 ↗
41. 10.2147/DDDT.S10439510.2147/DDDT.S104395 ↗
42. 10.2174/156720181666618112017013710.2174/1567201816666181120170137 ↗
43. 10.1002/wnan.4810.1002/wnan.48 ↗
44. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
45. 10.1016/j.apsb.2021.04.00110.1016/j.apsb.2021.04.001 ↗
46. 10.1002/eji.20124239410.1002/eji.201242394 ↗
47. 10.1073/pnas.150296711210.1073/pnas.1502967112 ↗